GoodRx Holdings (GDRX) Accumulated Expenses (2019 - 2026)

GoodRx Holdings has disclosed Accumulated Expenses across 8 years of filings, most recently posting $98.6 million for Q2 2026.

• In Q2 2026, Accumulated Expenses rose 3.07% year-over-year to $98.6 million; the TTM figure through Jun 2026 stood at $98.6 million (up 3.07% YoY), while the FY2025 annual figure was $86.7 million, up 4.05% from the prior year.
• Accumulated Expenses came in at $98.6 million for Q2 2026 at GoodRx Holdings, up from $83.7 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $143.4 million in Q3 2025 to a low of $33.8 million in Q1 2022.
• Average Accumulated Expenses over 5 years is $75.4 million, with a median of $73.9 million recorded in 2023.
• Year-over-year, Accumulated Expenses decreased 6.33% in 2022 and jumped 54.7% in 2025.
• Over 5 years, Accumulated Expenses stood at $47.5 million in 2022, then surged by 50.09% to $71.3 million in 2023, then climbed by 16.83% to $83.3 million in 2024, then advanced by 4.05% to $86.7 million in 2025, then rose by 13.73% to $98.6 million in 2026.
• Per Business Quant data, the three most recent Accumulated Expenses figures were $98.6 million in Q2 2026, $83.7 million in Q1 2026, and $86.7 million in Q4 2025.